Search

Your search keyword '"Chen, Chih‐Jung"' showing total 753 results
Start Over Author "Chen, Chih‐Jung" Language english
753 results on '"Chen, Chih‐Jung"'

9. Clinical practice consensus for the diagnosis and management of melanoma in Taiwan

Author

Wu, Chiao-En, Liao, Yi-Hua, Wu, Cheng-Lin, Yen, Ruoh-Fang, Lin, Chia-Chi, Yang, Muh-Hwa, Yen, Chueh-Chuan, Su, Wu-Chou, Yen, Chia-Jui, Chang, Yi-Fang, Wu, Ming-Fang, Yang, Youngsen, Lin, Chen-Yuan, Yang, Wen-Chi, Wang, Hui-Ching, Li, Cheng-Yuan, Ho, Yin-Yu, Chang, Yao-Yu, Wu, Chieh-Shan, Hsu, Hsiu-Cheng, Chen, Kuang-Hua, Huang, Yenlin, Chen, Chih-Jung, Chuang, Pei-Ju, Lai, Yung-Chi, Huang, Yu-Yi, Tseng, Neng-Chuan, Huang, Yi-Ting, Chu, Chia-Yu, and Wen-Cheng Chang, John

Published
2024
Full Text
View/download PDF

18. A hospital cluster of COVID-19 associated with a SARS-CoV-2 superspreading event

Author

Huang, Li-Yueh, Chiu, Yueh-Pi, Hou, Kuei-Chu, Chen, Mei-Lien, Huang, Yu-Chuan, Tsai, Li-Mei, Su, Yu-Hua, Wu, Hsiu-Ping, Liu, Shu-Ling, Wang, Hsiao-Ni, Chang, Li-Fang, Shen, Shu-Hui, Hung, Yun-Chi, Liu, En-Chi, Chen, Yi-Chuan, Yeh, Chiu-Lan, Chang, Hsiao-Chi, Chen, Yu-Ching, Wu, Ya-Ting, Wang, Ching-Yu, Lu, Yi-Rong, Ge, Mao-Cheng, Yang, Jeng-How, Wu, Yen-Mu, Huang, Po-Yen, Wu, Ting-Shu, Cheng, Chun-Wen, Chen, Chih-Jung, Huang, Chung-Guei, Tsao, Kuo-Chien, Lin, Chun-Sui, Chung, Ting-Ying, Lai, Chi-Chun, Yang, Cheng - Ta, Chen, Yi-Ching, and Chiu, Cheng-Hsun

Published
2022
Full Text
View/download PDF

24. Evaluation of Vaccine Strategies among Healthcare Workers during COVID-19 Omicron Outbreak in Taiwan.

Author

Lin, Min-Ru, Huang, Chung-Guei, Chiu, Cheng-Hsun, and Chen, Chih-Jung

Subjects
MEDICAL personnel, COVID-19 pandemic, BOOSTER vaccines, COVID-19 vaccines, VACCINE immunogenicity, ADENOVIRUS diseases
Abstract

Background/Objectives: This study aimed to assess the reactogenicity and immunogenicity of various SARS-CoV-2 vaccines and compare their protective effects against COVID-19 among healthcare workers (HCWs) during the Omicron outbreak in Taiwan. Methods: Conducted from March 2021 to July 2023, this prospective observational study included healthy HCWs without prior COVID-19 immunization. Participants chose between adenovirus-vectored (AstraZeneca), mRNA (Moderna, BioNTech-Pfizer), and protein-based (Medigen, Novavax) vaccines. Blood samples were taken at multiple points to measure neutralizing antibody (nAb) titers, and adverse events (AEs) were recorded via questionnaires. Results: Of 710 HCWs, 668 (94.1%) completed three doses, and 290 (40.8%) received a fourth dose during the Omicron outbreak. AEs were more common with AstraZeneca and Moderna vaccines, while Medigen caused fewer AEs. Initial nAb titers were highest with Moderna but waned over time regardless of the vaccine. Booster doses significantly increased nAb titers, with the highest levels observed in Moderna BA1 recipients. The fourth dose significantly reduced COVID-19 incidence, with Moderna BA1 being the most effective. Conclusions: Regular booster doses, especially with mRNA and adjuvant-protein vaccines, effectively enhance nAb levels and reduce infection rates, providing critical protection for frontline HCWs during variant outbreaks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing

Author

Ng, Cedric Chuan Young, Md Nasir, Nur Diyana, Loke, Benjamin Nathanael, Tay, Timothy Kwang Yong, Thike, Aye Aye, Rajasegaran, Vikneswari, Liu, Wei, Lee, Jing Yi, Guan, Peiyong, Lim, Abner Herbert, Chang, Kenneth Tou En, Gudi, Mihir Ananta, Madhukumar, Preetha, Tan, Benita Kiat Tee, Tan, Veronique Kiak Mien, Wong, Chow Yin, Yong, Wei Sean, Ho, Gay Hui, Ong, Kong Wee, International Fibroepithelial Consortium, Rahman, Norraha Abd, Begum, S. M. Khodeza Nahar, Cheah, Phaik Leng, Chen, Chih Jung, Fuente, Emmanuel Dela, Han, Aaron, Harada, Oi, Kanomata, Naoki, Lee, Cheok Soon, Lee, Jonathan Yu Han, Kamal, Mohammed, Nishimura, Rieko, Ohi, Yasuyo, Sawyer, Elinor J., Teoh, Kean Hooi, Tsang, Alex Koon Ho, Tsang, Julia Yuen-Shan, Tse, Gary M.K., and Yamaguchi, Rin

Published
2021
Full Text
View/download PDF

29. Secreted Frizzled-Related Protein 4 Induces Gastric Cancer Progression and Resistance to Cisplatin and Oxaliplatin via β-Catenin Dysregulation.

Author

Chen, Chun-Han, Chen, Chih-Jung, Huang, Yi-Ching, Huang, Po-Shuan, Chi, Hsiang-Cheng, Chuang, Huei-Chieh, Lin, Meng-Hung, Huang, Tzu-Hao, Hsu, Jun-Te, and Chen, Cheng-Yi

Subjects
*SECRETED frizzled-related proteins, *STOMACH cancer, *DRUG therapy, *CANCER patients, *CISPLATIN
Abstract

Introduction: Gastric cancer is the fifth most common cancer and third leading cause of cancer-related death worldwide. There are three main ways to treat gastric cancer: surgical resection, radiation therapy, and drug therapy. Furthermore, combinations of two to three regimens can improve survival. However, the survival outcomes of chemotherapy in advanced gastric cancer patients are still unsatisfactory. Unfortunately, no widely useful biomarkers have been verified to predict the efficacy of chemotherapy for locally advanced gastric cancer. Methods: An MTT assay was used to determine the cell viability after cisplatin or oxaliplatin treatment. Western blotting and immunohistochemistry were utilized to examine the secreted frizzled-related protein 4 (sFRP4) level and associated signaling pathways. Immunofluorescence staining was utilized to analyze the location of β-catenin. Colony formation and Transwell assays were used to analyze the functions related with cisplatin, oxaliplatin, and sFRP4. Results: We have found that gastric cancer patients treated with combinations of 5-fluorouracil (5-FU) and cisplatin regimens have better survival rates than those treated with 5-FU-based chemotherapy alone. sFRP4 was selected as a potential target from stringent analysis and intersection of 5-FU and cisplatin resistance-related gene sets. sFRP4 was shown to be overexpressed in clinical gastric tumor tissues and positively correlated with a worse survival rate. In addition, sFRP4 and β-catenin were upregulated in cisplatin- and oxaliplatin-resistant gastric cancer cells compared to parental cells. Immunofluorescence staining and nuclear fractionation showed that β-catenin was translocated from the cytosol into the nucleus. Moreover, sFRP4 was detected in the conditioned medium of these resistant cells, which indicates that sFRP4 might have an extracellular role in chemotherapy resistance. Increased migration capacity and dysregulation of epithelial-mesenchymal transition-related markers, which might result from the dysregulation of sFRP4, were observed in cisplatin- and oxaliplatin-resistant gastric cancer cells. Discussion/Conclusion: In summary, sFRP4 might play a critical role in resistance to cisplatin and oxaliplatin, cell metastasis, and poor prognosis in gastric cancer via the Wnt-β-catenin pathway. Investigations of the molecular mechanism underlying sFRP4-modulated cancer progression and chemotherapeutic outcomes can provide additional therapeutic strategies for gastric cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Invasive cribriform carcinoma of the breast presenting as an erythematous papule on the nipple: A case report.

Author

Chen, Po‐Yu, Ho, Yu‐Hsuan, Chen, Chih‐Jung, and Chiu, Chien‐Shan

Subjects
LOBULAR carcinoma, CARCINOMA, CUTANEOUS manifestations of general diseases, EPIDERMIS
Abstract

Key Clinical Message: Invasive cribriform carcinoma (ICC) is a rare form of invasive breast carcinoma with good prognosis. To date, case reports considering skin manifestations of ICC are scarce. We herein report a case of pure ICC presenting as an erythematous papule on the nipple with mammary Paget's disease in the epidermis. We aim to bring awareness to skin manifestation of ICC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.

Author

Chen, Wei‐Yu, Hu, Yu‐Hsuan, Tsai, Yu‐Hsin, Hang, Jen‐Fan, Tan, Puay Hoon, and Chen, Chih‐Jung

Subjects
BREAST, WHOLE genome sequencing, IMMUNOSTAINING, HARBORS, POLYMERASE chain reaction, DRUG target
Abstract

Aims: Breast mucinous cystadenocarcinoma (BMCA) is a rare tumour recently recognised as a distinct entity by the World Health Organisation Tumour Classification Series. BMCA is a triple‐negative tumour that lacks specific immunohistochemical markers; therefore, distinguishing it from mimickers such as ovarian and pancreatic cystadenocarcinomas requires careful clinicopathological correlation. Due to its rarity, little is known about the molecular alterations that underlie BMCA. Methods and results: In this study, we used immunohistochemical staining methods to investigate TRPS1 (trichorhinophalangeal syndrome type 1) expression in BMCA and compare it to expression in ovarian and pancreatic mucinous cystadenocarcinomas. We also collected tumour samples from three BMCA patients for molecular analysis by MALDI‐TOF mass spectrometry, real‐time polymerase chain reaction, whole exome sequencing and fluorescence in‐situ hybridisation. TRPS1 immunoreactivity was found only in BMCA tumour cells and not in the ovarian and pancreatic counterparts. One of the three BMCA tumours also showed a PIK3CA hot‐spot mutation, which was confirmed by whole genome next‐generation sequencing (NGS). No KRAS, NRAS, BRAF or AKT mutations were found. Conclusions: To our knowledge, this is the first demonstration of TRPS1 expression in BMCA patients and the first identification of a PIK3CA hotspot mutation in these tumours. These findings provide insights into the molecular mechanisms underlying BMCA tumorigenesis and suggest a potential drug target for this rare and poorly understood cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Cost‐effectiveness analysis of cell‐based versus egg‐based quadrivalent influenza vaccines in the pediatric population in Taiwan.

Author

Chi, Chia‐Yu, Cheng, Ming‐Fang, Ko, Karam, Mould, Joaquin F., Chen, Chih‐Jung, Huang, Yhu‐Chering, and Lee, Ping‐Ing

Subjects
INFLUENZA vaccines, CHILD patients, COST effectiveness, VACCINE effectiveness, VACCINATION coverage
Abstract

Cell‐based influenza vaccines avoid egg‐adaptive mutations, potentially improving vaccine effectiveness. We assessed the one‐season cost‐effectiveness of cell‐based quadrivalent influenza vaccine (QIVc) against that of egg‐derived quadrivalent influenza vaccines (QIVe) in children (6 months to 17 years of age) from payer and societal perspectives in Taiwan using an age‐stratified static model. Base case and high egg adaptation scenarios were assessed. Deterministic and probabilistic sensitivity analyses were performed. The incremental cost‐effectiveness ratio (ICER) threshold in Taiwan was assumed to be USD 99 177/quality‐adjusted life year (QALY). Compared to QIVe, QIVc would prevent 15 665 influenza cases, 2244 complicated cases, and 259 hospitalizations per year. The base case ICER was USD 68 298/QALY and USD 40 085/QALY from the payer and societal perspective, respectively. In the high egg adaptation scenario, the ICER was USD 45 782/QALY from the payer's perspective and USD 17 489/QALY from the societal perspective. Deterministic sensitivity analyses indicated that infection incidence rate, vaccination coverage, and prevalence of the A/H3N2 strain were the main drivers of ICER. In conclusion, switching the immunization strategy from QIVe to QIVc is predicted to reduce the influenza‐associated disease burden and be cost‐effective for the pediatric population in Taiwan. The potential benefits of QIVc would be even higher during influenza seasons with high levels of egg adaptation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results